Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in first-line advanced non-squamous NSCLC
2006-002688-26Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Sorafenib + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival. Started Nov 2006; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-002688-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002688-26.